中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

几丁质酶样蛋白40与肝纤维化的关系

史佳伟 黄晶

史佳伟, 黄晶. 几丁质酶样蛋白40与肝纤维化的关系[J]. 临床肝胆病杂志, 2021, 37(9): 2203-2205. DOI: 10.3969/j.issn.1001-5256.2021.09.040
引用本文: 史佳伟, 黄晶. 几丁质酶样蛋白40与肝纤维化的关系[J]. 临床肝胆病杂志, 2021, 37(9): 2203-2205. DOI: 10.3969/j.issn.1001-5256.2021.09.040
SHI JW, HUANG J. Association between YKL-40 and liver fibrosis[J]. J Clin Hepatol, 2021, 37(9): 2203-2205. DOI: 10.3969/j.issn.1001-5256.2021.09.040
Citation: SHI JW, HUANG J. Association between YKL-40 and liver fibrosis[J]. J Clin Hepatol, 2021, 37(9): 2203-2205. DOI: 10.3969/j.issn.1001-5256.2021.09.040

几丁质酶样蛋白40与肝纤维化的关系

DOI: 10.3969/j.issn.1001-5256.2021.09.040
基金项目: 

吉林省科技厅重点研发项目 20200404167YY

详细信息
    通讯作者:

    黄晶,jluhuangjing1@126.com

  • 中图分类号: R575.2

Association between YKL-40 and liver fibrosis

Funds: 

Jilin Province Science and Technology Development Program 20200404167YY

  • 摘要: 几丁质酶样蛋白40(YKL-40)是一种新兴的炎性标志物,肝脏表达水平最高。总结了YKL-40作为肝脏纤维化血清学标志物的研究进展。分析表明YKL-40能够有效评估肝脏纤维化的严重程度,具有良好的临床应用前景。由于单一指标诊断效能有限,建立YKL-40诊断模型与其他血清学指标联合应用将是未来的研究热点。

     

  • [1] COLL M, PEREA L, BOON R, et al. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis[J]. Cell Stem Cell, 2018, 23(1): 101-113.e7. DOI: 10.1016/j.stem.2018.05.027.
    [2] MEHTA KJ, FARNAUD SJ, SHARP PA. Iron and liver fibrosis: Mechanistic and clinical aspects[J]. World J Gastroenterol, 2019, 25(5): 521-538. DOI: 10.3748/wjg.v25.i5.521.
    [3] BERUMEN J, BAGLIERI J, KISSELEVA T, et al. Liver fibrosis: Pathophysiology and clinical implications[J]. Wiley Interdiscip Rev Syst Biol Med, 2021, 13(1): e1499. DOI: 10.1002/wsbm.1499.
    [4] ELLIS EL, MANN DA. Clinical evidence for the regression of liver fibrosis[J]. J Hepatol, 2012, 56(5): 1171-1180. DOI: 10.1016/j.jhep.2011.09.024.
    [5] TAPPER EB, LOOMBA R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(5): 274-282. DOI: 10.1038/nrgastro.2018.10.
    [6] AGBIM U, ASRANI SK. Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(4): 361-374. DOI: 10.1080/17474124.2019.1579641.
    [7] GUO T, HU B, YI WM, et al. Research advances in the serological diagnosis of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(11): 2579-2583. DOI: 10.3969/j.issn.1001-5256.2020.11.041.

    郭滔, 胡波, 易为民, 等. 血清学诊断非酒精性脂肪性肝病的研究进展[J]. 临床肝胆病杂志, 2020, 36(11): 2579-2583. DOI: 10.3969/j.issn.1001-5256.2020.11.041.
    [8] TEMEL Y İ, ASLAN ÇETIN B, KÖROĞLU N, et al. Inflammatory marker YKL-40 levels in intrahepatic cholestasis of pregnancy[J]. Gynecol Endocrinol, 2019, 35(7): 635-637. DOI: 10.1080/09513590.2018.1563889.
    [9] ZHAO T, SU Z, LI Y, et al. Chitinase-3 like-protein-1 function and its role in diseases[J]. Signal Transduct Target Ther, 2020, 5(1): 201. DOI: 10.1038/s41392-020-00303-7.
    [10] NGERNYUANG N, SHAO R, SUWANNARURK K, et al. Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer[J]. Pathology, 2018, 50(3): 293-297. DOI: 10.1016/j.pathol.2017.09.015.
    [11] ILMARINEN P, TUOMISTO LE, NIEMELÄ O, et al. YKL-40 and adult-onset asthma: Elevated levels in clusters with poorest outcome[J]. J Allergy Clin Immunol Pract, 2019, 7(7): 2466-2468.e3. DOI: 10.1016/j.jaip.2019.03.043.
    [12] SUZUKI H, BOKI H, KAMIJO H, et al. YKL-40 promotes proliferation of cutaneous T-Cell lymphoma tumor cells through extracellular signal-regulated kinase pathways[J]. J Invest Dermatol, 2020, 140(4): 860-868.e3. DOI: 10.1016/j.jid.2019.09.007.
    [13] SUN Y, SHI Z, LIU B, et al. YKL-40 mediates airway remodeling in asthma via activating FAK and MAPK signaling pathway[J]. Cell Cycle, 2020, 19(11): 1378-1390. DOI: 10.1080/15384101.2020.1750811.
    [14] LIU L, ZHANG X, LIU Y, et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations[J]. Respir Res, 2019, 20(1): 95. DOI: 10.1186/s12931-019-1051-9.
    [15] JAFARI-NAKHJAVANI MR, GHORBANIHAGHJO A, BAGHERZADEH-NOBARI B, et al. Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis[J]. Caspian J Intern Med, 2019, 10(1): 92-97. DOI: 10.22088/cjim.10.1.92.
    [16] CHIRINOS JA, ORLENKO A, ZHAO L, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction[J]. J Am Coll Cardiol, 2020, 75(11): 1281-1295. DOI: 10.1016/j.jacc.2019.12.069.
    [17] ŚCIBORSKI K, KULICZKOWSKI W, KAROLKO B, et al. Plasma YKL-40 levels correlate with the severity of coronary atherosclerosis assessed with the SYNTAX score[J]. Pol Arch Intern Med, 2018, 128(11): 644-648. DOI: 10.20452/pamw.4345.
    [18] DEZSO Z, NIKOLSKY Y, SVIRIDOV E, et al. A comprehensive functional analysis of tissue specificity of human gene expression[J]. BMC Biol, 2008, 6: 49. DOI: 10.1186/1741-7007-6-49.
    [19] ANDERSSON R, GEBHARD C, MIGUEL-ESCALADA I, et al. An atlas of active enhancers across human cell types and tissues[J]. Nature, 2014, 507(7493): 455-461. DOI: 10.1038/nature12787.
    [20] SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7.
    [21] JOHANSEN JS, MØLLER S, PRICE PA, et al. Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis?[J]. Scand J Gastroenterol, 1997, 32(6): 582-590. DOI: 10.3109/00365529709025104.
    [22] TRAN A, BENZAKEN S, SAINT-PAUL MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease[J]. Eur J Gastroenterol Hepatol, 2000, 12(9): 989-993. DOI: 10.1097/00042737-200012090-00004.
    [23] YOUNOSSI ZM, LOOMBA R, ANSTEE QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis[J]. Hepatology, 2018, 68(1): 349-360. DOI: 10.1002/hep.29721.
    [24] KUMAGAI E, MANO Y, YOSHIO S, et al. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J]. Sci Rep, 2016, 6: 35282. DOI: 10.1038/srep35282.
    [25] FU LK, SHENG LN, ZOU CY, et al. Correlation between serum fibrosis markers and intrahepatic fat content in patients with nonalcoholic fatty liver disease[J/CD]. Chin J Oper Proc Gen Surg(Electronic Version), 2019, 13(4): 385-387. DOI: 10.3877/cma.j.issn.1674-3946.2019.04.020.

    付丽坤, 盛丽娜, 邹春燕, 等. 非酒精性脂肪性肝病患者血清肝纤维化指标与肝内脂肪含量的相关性研究[J/CD]. 中华普外科手术学杂志(电子版), 2019, 13(4): 385-387. DOI: 10.3877/cma.j.issn.1674-3946.2019.04.020.
    [26] BUKH J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control[J]. J Hepatol, 2016, 65(1 Suppl): s2-s21. DOI: 10.1016/j.jhep.2016.07.035.
    [27] CHIGBU DI, LOONAWAT R, SEHGAL M, et al. Hepatitis C virus infection: Host virus interaction and mechanisms of viral persistence[J]. Cells, 2019, 8(4): 376. DOI: 10.3390/cells8040376.
    [28] FONTANA RJ, DIENSTAG JL BONKOVSKY HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C[J]. Gut, 2010, 59(10): 1401-1409. DOI: 10.1136/gut.2010.207423.
    [29] ESMAT G, METWALLY M, ZALATA KR, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C[J]. J Hepatol, 2007, 46(4): 620-627. DOI: 10.1016/j.jhep.2006.12.010.
    [30] ZOHEIRY MM, HASAN SA, EL-AHWANY E, et al. Serum markers of epithelial mesenchymal transition as predictors of HCV-induced liver fibrosis, cirrhosis and hepatocellular carcinoma[J]. Electron Physician, 2015, 7(8): 1626-1637. DOI: 10.19082/1626.
    [31] MEGAHED F, ZHOU X, SUN P. The interactions between HBV and the innate immunity of hepatocytes[J]. Viruses, 2020, 12(3): 385. DOI: 10.3390/v12030285.
    [32] NIU XJ, LIU ZH, CUI FM, et al. Predictive value of systemic inflammatory indexes on progression of hepatitis B-related liver cirrhosis and hepatitis B virus-related hepatocellular carcinoma[J/CD]. Chin J Liver Dis(Electronic Edition), 2020, 12(2): 1-9. DOI: 10.3969/j.issn.1674-7380.2020.02.001.

    牛兴杰, 刘志慧, 崔凤梅, 等. 系统炎症指标在乙型肝炎肝硬化及乙型肝炎病毒相关肝细胞癌进展中的预测价值[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(2): 1-9. DOI: 10.3969/j.issn.1674-7380.2020.02.001.
    [33] YANG Q, LYU XY, WANG Z. The value of YKL-40 and PCPE-1 in evaluating the degree of liver fibrosis in patients with chronic hepatitis B[J]. Chin Hepatol, 2019, 24(3): 309-312. DOI: 10.3969/j.issn.1008-1704.2019.03.033.

    杨启, 吕新远, 王哲. YKL-40、PCPE-1对慢性乙型肝炎患者肝纤维化程度的评估价值[J]. 肝脏, 2019, 24(3): 309-312. DOI: 10.3969/j.issn.1008-1704.2019.03.033.
    [34] YAN L, DENG Y, ZHOU J, et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection, 2018, 46(3): 385-393. DOI: 10.1007/s15010-018-1136-2.
    [35] LONG X, HE X, OHSHIMO S, et al. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis[J]. Eur Respir J, 2017, 49(2). DOI: 10.1183/13993003.01924-2015.
    [36] BIAN B, LI L, YANG J, et al. Prognostic value of YKL-40 in solid tumors: A meta-analysis of 41 cohort studies[J]. Cancer Cell Int, 2019, 19: 259. DOI: 10.1186/s12935-019-0983-y.
    [37] FONTANA RJ, BONKOVSKY HL, NAISHADHAM D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2009, 7(2): 219-226. DOI: 10.1016/j.cgh.2008.10.034.
    [38] NØJGAARD C, JOHANSEN JS, CHRISTENSEN E, et al. Serum levels of YKL-40 and PⅢNP as prognostic markers in patients with alcoholic liver disease[J]. J Hepatol, 2003, 39(2): 179-186. DOI: 10.1016/s0168-8278(03)00184-3.
  • 加载中
计量
  • 文章访问数:  32
  • HTML全文浏览量:  11
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-01-25
  • 修回日期:  2021-04-28
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回